Exarchou, Klaire
Stephens, Nathan A.
Moore, Andrew R.
Howes, Nathan R.
Pritchard, D. Mark
Article History
Accepted: 21 October 2021
First Online: 20 January 2022
Declarations
:
: Klaire Exarchou has received speaker’s honoraria from Ipsen. Nathan A. Stephens declares that he has no conflict of interest. Andrew R. Moore has received speaker’s honoraria from Dr. Falk Pharma GmbH, and has received reimbursement for travel accommodations/expenses from Ipsen. Nathan R. Howes is supported, in part, by a research grant from the UK and Ireland Neuroendocrine Tumour Society (UKINETS)/Neuroendocrine Cancer UK. D. Mark Pritchard is supported, in part, by a research grant from UKINETS/Neuroendocrine Cancer UK, and has received research funding to investigate the role of netazepide in gastric NETs from Trio Medicines Ltd.; has served as a consultant for Ipsen, Advanced Accelerator Applications, and Laboratoires Mayoly-Spindler, with all compensation going directly to his institution; has served as a guest lecturer/speaker/presenter for Ipsen, Advanced Accelerator Applications, and Laboratoires Mayoly-Spindler, with all compensation going directly to his institution; has received reimbursement for travel accommodations/expenses from Ipsen; has participated on a Data Safety Monitoring Board or Advisory Board for Ipsen and Advanced Accelerator Applications, with all compensation going directly to his institution; and was a member of the British Society of Gastroenterology Council from 2018 to 2020.
: This article does not contain any studies with human or animal subjects performed by any of the authors.